Literature DB >> 29472616

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.

Tomer Cooks1, Ioannis S Pateras2, Lisa M Jenkins3, Keval M Patel4, Ana I Robles1, James Morris5, Tim Forshew6, Ettore Appella3, Vassilis G Gorgoulis2,7,8, Curtis C Harris9.   

Abstract

TP53 mutants (mutp53) are involved in the pathogenesis of most human cancers. Specific mutp53 proteins gain oncogenic functions (GOFs) distinct from the tumor suppressor activity of the wild-type protein. Tumor-associated macrophages (TAMs), a hallmark of solid tumors, are typically correlated with poor prognosis. Here, we report a non-cell-autonomous mechanism, whereby human mutp53 cancer cells reprogram macrophages to a tumor supportive and anti-inflammatory state. The colon cancer cells harboring GOF mutp53 selectively shed miR-1246-enriched exosomes. Uptake of these exosomes by neighboring macrophages triggers their miR-1246-dependent reprogramming into a cancer-promoting state. Mutp53-reprogammed TAMs favor anti-inflammatory immunosuppression with increased activity of TGF-β. These findings, associated with poor survival in colon cancer patients, strongly support a microenvironmental GOF role for mutp53 in actively engaging the immune system to promote cancer progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29472616      PMCID: PMC5823939          DOI: 10.1038/s41467-018-03224-w

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  65 in total

1.  Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.

Authors:  Maria Francesca Baietti; Zhe Zhang; Eva Mortier; Aurélie Melchior; Gisèle Degeest; Annelies Geeraerts; Ylva Ivarsson; Fabienne Depoortere; Christien Coomans; Elke Vermeiren; Pascale Zimmermann; Guido David
Journal:  Nat Cell Biol       Date:  2012-06-03       Impact factor: 28.824

2.  p53 downregulates Down syndrome-associated DYRK1A through miR-1246.

Authors:  Yu Zhang; Jun-Ming Liao; Shelya X Zeng; Hua Lu
Journal:  EMBO Rep       Date:  2011-06-03       Impact factor: 8.807

3.  Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.

Authors:  G Bossi; E Lapi; S Strano; C Rinaldo; G Blandino; A Sacchi
Journal:  Oncogene       Date:  2006-01-12       Impact factor: 9.867

4.  Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer.

Authors:  Gwangil Kim; Hee-Jung An; Mi-Jung Lee; Ji-Ye Song; Ju-Yeon Jeong; Ji-Hyun Lee; Hye-Cheol Jeong
Journal:  Lung Cancer       Date:  2015-11-17       Impact factor: 5.705

5.  Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo.

Authors:  Ming Kei Lee; Wei Wei Teoh; Beng Hooi Phang; Wei Min Tong; Zhao Qi Wang; Kanaga Sabapathy
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 6.  Therapeutic applications of extracellular vesicles: clinical promise and open questions.

Authors:  Bence György; Michelle E Hung; Xandra O Breakefield; Joshua N Leonard
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-03       Impact factor: 13.820

7.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.

Authors:  Marco Erreni; Alberto Mantovani; Paola Allavena
Journal:  Cancer Microenviron       Date:  2010-09-17

Review 8.  Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis.

Authors:  Marco Cordani; Raffaella Pacchiana; Giovanna Butera; Gabriella D'Orazi; Aldo Scarpa; Massimo Donadelli
Journal:  Cancer Lett       Date:  2016-04-01       Impact factor: 8.679

9.  Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

Authors:  Qiong-wen Zhang; Lei Liu; Chang-yang Gong; Hua-shan Shi; Yun-hui Zeng; Xiao-ze Wang; Yu-wei Zhao; Yu-quan Wei
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

10.  Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology.

Authors:  Mukesh Verma; Tram Kim Lam; Elizabeth Hebert; Rao L Divi
Journal:  BMC Clin Pathol       Date:  2015-04-15
View more
  153 in total

Review 1.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

2.  SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC.

Authors:  Chunlai Yin; Qiuju Han; Dongqing Xu; Bingqing Zheng; Xuemei Zhao; Jian Zhang
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

Review 3.  Exosomes in cancer development, metastasis, and immunity.

Authors:  Lin Zhang; Dihua Yu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-30       Impact factor: 10.680

Review 4.  The p53 Saga: Early Steps in the Development of Tumor Immunotherapy.

Authors:  Albert B DeLeo; Ettore Appella
Journal:  J Immunol       Date:  2020-05-01       Impact factor: 5.422

Review 5.  Exosome-mediated cell-cell communication in tumor progression.

Authors:  Zhuo Wan; Xiaotong Gao; Yan Dong; Yingxin Zhao; Xutao Chen; Guodong Yang; Li Liu
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

Review 6.  Bi-direction effects between microbiome and MiRNAs in carcinogenesis.

Authors:  Qinglin Wang; Hanlin Ding; Gaochao Dong; Lin Xu; Feng Jiang; Qixing Mao
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-25       Impact factor: 4.553

7.  Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.

Authors:  Lejia Sun; Huayu Yang; Ai Guan; Huanhuan Yin; Meixi Liu; Xinxin Mao; Haifeng Xu; Haitao Zhao; Xin Lu; Xinting Sang; Shouxian Zhong; Qian Chen; Yilei Mao
Journal:  Cancer Immunol Immunother       Date:  2020-09-02       Impact factor: 6.968

8.  miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells.

Authors:  Xingju Zhang; Fei Li; Ying Tang; Qinglan Ren; Bin Xiao; Ying Wan; Shan Jiang
Journal:  Oncogene       Date:  2020-08-27       Impact factor: 9.867

Review 9.  Mutant p53 on the Path to Metastasis.

Authors:  Qiaosi Tang; Zhenyi Su; Wei Gu; Anil K Rustgi
Journal:  Trends Cancer       Date:  2019-12-16

Review 10.  MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages.

Authors:  Chong Chen; Jia-Ming Liu; Yun-Ping Luo
Journal:  J Zhejiang Univ Sci B       Date:  2020 Jan.       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.